Abstract
Abstract: This narrative review delves into the potential therapeutic implications of semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, in the context of Substance Use Disorders (SUDs). By systematically exploring databases from 2011 to 2023, and incorporating foundational works from 2004, a total of 59 articles were identified as pertinent to the topic. Utilizing the SANRA scale for assessment, the quality and relevance of these studies were rigorously evaluated. Preliminary findings indicate that semaglutide may play a pivotal role in modulating behaviors associated with SUDs, potentially providing fresh perspectives on the neurobiological mechanisms underlying these disorders. While the precise pathways of action for semaglutide remain to be fully deciphered, its recurrent mention in the literature underscores its emerging importance in the field of SUD research. As the understanding of semaglutide's influence expands, it holds promise as a focal point in future studies, warranting further in-depth exploration to ascertain its full therapeutic potential.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
